# Pulmonx Corporation (LUNG)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $58M  
**Price:** $1.42 (-0.70%)

> Pulmonx Corporation is a leading medical technology company specializing in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The company focuses on developing and commercializing advanced technologies that offer new options for patients suffering from lung disorders. One of its flagship products, the Zephyr Valve, is a tiny device designed for bronchoscopic lung volume reduction in severe emphysema patients, providing an alternative to invasive surgical procedures. Pulmonx's innovative solutions impact the healthcare sector by improving patient outcomes and offering healthcare providers effective, less invasive treatment options. By driving advancements in respiratory care, Pulmonx plays a significant role in the growing medical device industry, particularly within the respiratory segment, as the demand for novel therapeutic options for chronic lung diseases increases. Headquartered in Redwood City, California, the company collaborates with medical professionals worldwide to expand access to its life-changing technologies.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $90M | $67M | -$54M | -$54M | $-1.33 |
| 2024 | $84M | $62M | -$58M | -$56M | $-1.44 |
| 2023 | $69M | $51M | -$62M | -$61M | $-1.60 |
| 2022 | $54M | $40M | -$59M | -$59M | $-1.59 |
| 2021 | $48M | $36M | -$47M | -$49M | $-1.35 |
| 2020 | $33M | $21M | -$32M | -$32M | $-3.16 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $129M | $75M | $54M | $70M | $55M |
| 2024 | $163M | $77M | $86M | $71M | $53M |
| 2023 | $178M | $59M | $118M | $84M | $36M |
| 2022 | $194M | $40M | $154M | $102M | $21M |
| 2021 | $235M | $42M | $193M | $148M | $24M |
| 2020 | $264M | $38M | $226M | $232M | $25M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$31M | -$452,000 | -$33M |
| 2024 | -$32M | -$1M | -$33M |
| 2023 | -$40M | -$807,000 | -$38M |
| 2022 | -$46M | -$1M | -$46M |
| 2021 | -$46M | -$4M | -$45M |
| 2020 | -$27M | -$911,000 | -$32M |

Source: [CompaniesByCap](https://companiesbycap.com/company/LUNG)